563 related articles for article (PubMed ID: 24681079)
21. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure.
Stevens V; Dumyati G; Brown J; Wijngaarden E
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1035-42. PubMed ID: 21833992
[TBL] [Abstract][Full Text] [Related]
22. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics.
Hensgens MP; Goorhuis A; Dekkers OM; Kuijper EJ
J Antimicrob Chemother; 2012 Mar; 67(3):742-8. PubMed ID: 22146873
[TBL] [Abstract][Full Text] [Related]
23. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
[TBL] [Abstract][Full Text] [Related]
24. Investigation to identify a resource-efficient case-control methodology for determining antibiotics associated with Clostridium difficile infection.
Chung P; Currie B; Guo Y; Talansky M; Brown S; Ostrowsky B
Am J Infect Control; 2014 Oct; 42(10 Suppl):S264-8. PubMed ID: 25239720
[TBL] [Abstract][Full Text] [Related]
25. Potential protective role of linezolid against Clostridium difficile infection.
Valerio M; Pedromingo M; Muñoz P; Alcalá L; Marin M; Peláez T; Giannella M; Bouza E
Int J Antimicrob Agents; 2012 May; 39(5):414-9. PubMed ID: 22445203
[TBL] [Abstract][Full Text] [Related]
26. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy.
Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW
J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with Clostridium difficile infection: A nested case-control study in a three year prospective cohort.
Khanafer N; Vanhems P; Barbut F; Luxemburger C; ; Demont C; Hulin M; Dauwalder O; Vandenesch F; ; Argaud L; Badet L; Barth X; Bertrand M; Burillon C; Chapurlat R; Chuzeville M; Comte B; Disant F; Fessy MH; Gouillat C; Juillard L; Lermusiaux P; Monneuse O; Morelon E; Ninet J; Ponchon T; Poulet E; Rimmele T; Tazarourte K
Anaerobe; 2017 Apr; 44():117-123. PubMed ID: 28279859
[TBL] [Abstract][Full Text] [Related]
28. Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting.
Scardina T; Labuszewski L; Pacheco SM; Adams W; Schreckenberger P; Johnson S
Infect Control Hosp Epidemiol; 2015 Mar; 36(3):280-6. PubMed ID: 25695169
[TBL] [Abstract][Full Text] [Related]
29. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
Dalton BR; Lye-Maccannell T; Henderson EA; Maccannell DR; Louie TJ
Aliment Pharmacol Ther; 2009 Mar; 29(6):626-34. PubMed ID: 19183143
[TBL] [Abstract][Full Text] [Related]
30. Assessing the risk and disease burden of Clostridium difficile infection among patients with hospital-acquired pneumonia at a University Hospital in Central China.
Li C; Duan J; Liu S; Meng X; Fu C; Zeng C; Wu A
Infection; 2017 Oct; 45(5):621-628. PubMed ID: 28497295
[TBL] [Abstract][Full Text] [Related]
31. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.
Kyne L; Sougioultzis S; McFarland LV; Kelly CP
Infect Control Hosp Epidemiol; 2002 Nov; 23(11):653-9. PubMed ID: 12452292
[TBL] [Abstract][Full Text] [Related]
32. Analysis of interventions to reduce the incidence of Clostridium difficile infection at a London teaching hospital trust, 2003-2011.
Marufu O; Desai N; Aldred D; Brown T; Eltringham I
J Hosp Infect; 2015 Jan; 89(1):38-45. PubMed ID: 25480022
[TBL] [Abstract][Full Text] [Related]
33. Preventing downstream Clostridium difficile infections with upstream antibiotic management.
Malkan AD; Scholand SJ
Med Hypotheses; 2012 Jan; 78(1):136-7. PubMed ID: 22079651
[TBL] [Abstract][Full Text] [Related]
34. Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients.
Shah K; Pass LA; Cox M; Lanham M; Arnold FW
J Trauma Acute Care Surg; 2012 Mar; 72(3):691-5. PubMed ID: 22491554
[TBL] [Abstract][Full Text] [Related]
35. Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence.
Islam J; Cheek E; Navani V; Rajkumar C; Cohen J; Llewelyn MJ
J Hosp Infect; 2013 Sep; 85(1):17-21. PubMed ID: 23910403
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology and risk factors for Clostridium difficile infection in children.
Sandora TJ; Fung M; Flaherty K; Helsing L; Scanlon P; Potter-Bynoe G; Gidengil CA; Lee GM
Pediatr Infect Dis J; 2011 Jul; 30(7):580-4. PubMed ID: 21233782
[TBL] [Abstract][Full Text] [Related]
37. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
[TBL] [Abstract][Full Text] [Related]
38. Obesity as a risk factor for Clostridium difficile infection.
Bishara J; Farah R; Mograbi J; Khalaila W; Abu-Elheja O; Mahamid M; Nseir W
Clin Infect Dis; 2013 Aug; 57(4):489-93. PubMed ID: 23645850
[TBL] [Abstract][Full Text] [Related]
39. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
40. Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Linsky A; Gupta K; Lawler EV; Fonda JR; Hermos JA
Arch Intern Med; 2010 May; 170(9):772-8. PubMed ID: 20458084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
